Luo Y, Wang LJ, Wang CL. Advancing the understanding and management of blastic plasmacytoid dendritic cell neoplasm: Insights from recent case studies. World J Clin Cases 2024; 12(31): 6441-6446 [DOI: 10.12998/wjcc.v12.i31.6441]
Corresponding Author of This Article
Cheng-Long Wang, MD, Doctor, Department of Pathology, The Chongqing Hospital of Traditional Chinese Medicine, No.6 Seventh Panxi Branch Road, Jiangbei District, Chongqing 400021, China. 171909771@qq.com
Research Domain of This Article
Pathology
Article-Type of This Article
Editorial
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Clin Cases. Nov 6, 2024; 12(31): 6441-6446 Published online Nov 6, 2024. doi: 10.12998/wjcc.v12.i31.6441
Advancing the understanding and management of blastic plasmacytoid dendritic cell neoplasm: Insights from recent case studies
Yan Luo, Li-Juan Wang, Cheng-Long Wang
Yan Luo, Department of Stomatology, The People's Hospital of Dadukou District, Chongqing 400084, China
Li-Juan Wang, Cheng-Long Wang, Department of Pathology, The Chongqing Hospital of Traditional Chinese Medicine, Chongqing 400021, China
Co-corresponding authors: Li-Juan Wang and Cheng-Long Wang.
Author contributions: Luo Y and Wang CL contributed to this paper; Wang LJ and Wang CL designed the overall concept and outline of the manuscript, contributed to the discussion, and design of the manuscript; Luo Y contributed to the writing and editing of the manuscript, and review of literature; all authors read and approved the final manuscript.
Supported byThe Chongqing Health Commission and Science and Technology Bureau, No. 2023MSXM060.
Conflict-of-interest statement: We have no financial relationships to disclose.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Cheng-Long Wang, MD, Doctor, Department of Pathology, The Chongqing Hospital of Traditional Chinese Medicine, No.6 Seventh Panxi Branch Road, Jiangbei District, Chongqing 400021, China. 171909771@qq.com
Received: June 15, 2024 Revised: July 15, 2024 Accepted: July 26, 2024 Published online: November 6, 2024 Processing time: 87 Days and 13.4 Hours
Abstract
We specifically discuss the mechanisms of the pathogenesis, diagnosis, and management of blastic plasmacytoid dendritic cell neoplasm (BPDCN), a rare but aggressive haematologic malignancy characterized by frequent skin manifestations and systemic dissemination. The article enriches our understanding of BPDCN through detailed case reports showing the clinical, immunophenotypic, and histopathological features that are critical for diagnosing this disease. These cases highlight the essential role of pathologists in employing advanced immunophenotyping techniques to accurately identify the disease early in its course and guide treatment decisions. Furthermore, we explore the implications of these findings for management strategies, emphasizing the use of targeted therapies such as tagraxofusp and the potential of allogeneic haematopoietic stem cell transplantation in achieving remission. The editorial underscores the importance of interdisciplinary approaches in managing BPDCN, pointing towards a future where precision medicine could significantly improve patient outcomes.
Core Tip: The editorial revisits the pathogenesis, diagnosis, and innovative management strategies for blastic plasmacytoid dendritic cell neoplasm, inspired by recent case reports. It underscores the critical role of advanced immunophenotyping in early and accurate diagnosis and highlights the promise of targeted therapies such as tagraxofusp and allogeneic haematopoietic stem cell transplantation for improved outcomes. Emphasizing interdisciplinary collaboration, this work points towards precision medicine as a future paradigm, aiming to transform the management and prognosis of this aggressive haematologic malignancy, thereby paving the way for more effective patient-specific therapeutic strategies.
